Arthur Ivan N Oliveira1, Fernanda M Malta1, Patricia Momoyo Y Zitelli1, Ana Paula M Salles1, Michele S Gomes-Gouvea1, Ana Catharina S Nastri2, Joao Renato R Pinho1, Flair J Carrilho1, Claudia P Oliveira1, Maria Cássia Mendes-Corrêa2, Mario G Pessoa1, Daniel F Mazo3,4. 1. Division of Clinical Gastroenterology and Hepatology, LIM07, Department of Gastroenterology, University of São Paulo School of Medicine (FMUSP), Av. Dr. Enéas de Carvalho Aguiar no 255, Instituto Central, # 9159, São Paulo, 05403-900, Brazil. 2. Department of Infectious Diseases, University of São Paulo School of Medicine (FMUSP), Av. Dr. Enéas de Carvalho Aguiar no 255, São Paulo, 05403-900, Brazil. 3. Division of Clinical Gastroenterology and Hepatology, LIM07, Department of Gastroenterology, University of São Paulo School of Medicine (FMUSP), Av. Dr. Enéas de Carvalho Aguiar no 255, Instituto Central, # 9159, São Paulo, 05403-900, Brazil. daniel.mazo@hc.fm.usp.br. 4. Division of Gastroenterology (Gastrocentro), School of Medical Sciences, University of Campinas (UNICAMP), Rua Carlos Chagas no 420, Campinas, 13083-878, Brazil. daniel.mazo@hc.fm.usp.br.
Abstract
BACKGROUND: Despite the growing body of knowledge about TM6SF2 and PNPLA3 polymorphisms in non-alcoholic fatty liver disease, their influence in the spectrum of HCV liver disease is not yet fully defined. Besides that, admixed populations, such as Brazilians, were not included in most of the studies. METHODS: This cross-sectional study enrolled 365 treatment-naïve patients with HCV and 134 healthy individuals. TM6SF2 (rs58542926 c.499C > T) and PNPLA3 (rs738409 c.444C > G) polymorphisms were evaluated regarding their association with clinical and laboratory data, histological liver steatosis and fibrosis, and with components of the metabolic syndrome. RESULTS: In HCV subjects, the frequencies of TM6SF2 CC and CT + TT were 89% and 11%, while PNPLA3 frequencies of CC and CG + GG were 51.4% and 48.6%. In the univariate logistic regression analysis, the TM6SF2 CT + TT genotype in HCV was associated with significant liver fibrosis (p = 0.047; OR 1.953; 95% CI 1.009-3.788). In comparison to the CT + TT genotype, the TM6SF2 CC genotype in HCV was associated with older age (p = 0.002), higher frequency of arterial hypertension (p = 0.032), obesity (p = 0.030), metabolic syndrome (p = 0.014) and lower total cholesterol levels (p = 0.036). The PNPLA3 GG subjects had lower body mass index than CG/ CC individuals (p = 0.047). None of the polymorphisms, or their combinations, was independently associated with hepatic steatosis or fibrosis. On the other hand, older age, lower serum levels of total cholesterol, and higher serum levels of alanine aminotransferase and alkaline phosphatase were associated with liver fibrosis in the multivariate logistic regression analysis. CONCLUSION: In this evaluation of an admixed HCV population, neither TM6SF2 nor PNPLA3 polymorphisms were independently associated with hepatic steatosis or fibrosis. Other factors seem more influential than these specific polymorphisms in isolation. More studies are warranted to clarify the role of the TM6SF2 and PNPLA3 polymorphisms in Brazilians with HCV.
BACKGROUND: Despite the growing body of knowledge about TM6SF2 and PNPLA3 polymorphisms in non-alcoholic fatty liver disease, their influence in the spectrum of HCV liver disease is not yet fully defined. Besides that, admixed populations, such as Brazilians, were not included in most of the studies. METHODS: This cross-sectional study enrolled 365 treatment-naïve patients with HCV and 134 healthy individuals. TM6SF2 (rs58542926 c.499C > T) and PNPLA3 (rs738409 c.444C > G) polymorphisms were evaluated regarding their association with clinical and laboratory data, histological liver steatosis and fibrosis, and with components of the metabolic syndrome. RESULTS: In HCV subjects, the frequencies of TM6SF2 CC and CT + TT were 89% and 11%, while PNPLA3 frequencies of CC and CG + GG were 51.4% and 48.6%. In the univariate logistic regression analysis, the TM6SF2 CT + TT genotype in HCV was associated with significant liver fibrosis (p = 0.047; OR 1.953; 95% CI 1.009-3.788). In comparison to the CT + TT genotype, the TM6SF2 CC genotype in HCV was associated with older age (p = 0.002), higher frequency of arterial hypertension (p = 0.032), obesity (p = 0.030), metabolic syndrome (p = 0.014) and lower total cholesterol levels (p = 0.036). The PNPLA3 GG subjects had lower body mass index than CG/ CC individuals (p = 0.047). None of the polymorphisms, or their combinations, was independently associated with hepatic steatosis or fibrosis. On the other hand, older age, lower serum levels of total cholesterol, and higher serum levels of alanine aminotransferase and alkaline phosphatase were associated with liver fibrosis in the multivariate logistic regression analysis. CONCLUSION: In this evaluation of an admixed HCV population, neither TM6SF2 nor PNPLA3 polymorphisms were independently associated with hepatic steatosis or fibrosis. Other factors seem more influential than these specific polymorphisms in isolation. More studies are warranted to clarify the role of the TM6SF2 and PNPLA3 polymorphisms in Brazilians with HCV.
Entities:
Keywords:
Genetic variation; Hepatitis C virus; Hepatitis virus
Authors: D Crisan; M Grigorescu; N Crisan; R Craciun; M Lupsor; C Radu; M D Grigorescu; A Suciu; F Epure; L Avram; N Leach Journal: J Physiol Pharmacol Date: 2019-10-19 Impact factor: 3.011
Authors: Julia Kozlitina; Eriks Smagris; Stefan Stender; Børge G Nordestgaard; Heather H Zhou; Anne Tybjærg-Hansen; Thomas F Vogt; Helen H Hobbs; Jonathan C Cohen Journal: Nat Genet Date: 2014-02-16 Impact factor: 38.330
Authors: Adele Schwartz Benzaken; Renato Girade; Elisa Catapan; Gerson Fernando Mendes Pereira; Elton Carlos de Almeida; Simone Vivaldini; Neide Fernandes; Homie Razavi; Jonathan Schmelzer; Maria Lucia Ferraz; Paulo Roberto Abrão Ferreira; Mario Guimarães Pessoa; Ana Martinelli; Francisco José Dutra Souto; Nick Walsh; Maria Cassia Mendes-Correa Journal: Braz J Infect Dis Date: 2019-05-27 Impact factor: 3.257